Insider · CIK 0001966716

Allan Jonathan

Reports to the SEC for 1 company · BEDFORD, MA

sec.gov

Transactions

Companies

Filings

CIK

0001966716

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-02	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−627 sh	$26.33	−$16.5K	20,598
2026-08-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−2,716 sh	$32.01	−$86.9K	21,370
2026-08-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−145 sh	$32.47	−$4,707.875	21,225
2026-08-14	STOKStoke Therapeutics, Inc. · Performance Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−6,000 sh	—	—	0
2026-08-14	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+6,000 sh	—	—	24,086
2026-06-16	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,457 sh	$29.95	−$43.6K	18,086
2026-03-20	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−8,692 sh	$33.64	−$292K	20,144
2026-03-20	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−601 sh	$34.41	−$20.7K	19,543
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−4,222 sh	$31.28	−$132K	29,242
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−72 sh	$32.85	−$2,365.2	28,836
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−334 sh	$31.79	−$10.6K	28,908
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,791 sh	$33.38	−$59.8K	33,464
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−2,476 sh	$32.74	−$81.1K	35,255
2026-03-15	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+6,000 sh	—	—	25,731
2026-03-15	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−6,000 sh	—	—	12,000
2026-03-15	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−7,475 sh	—	—	7,475
2026-03-15	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+12K sh	—	—	37,731
2026-03-15	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+7,475 sh	—	—	19,731
2026-03-15	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−12K sh	—	—	36,000
2026-02-17	STOKStoke Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	GENERAL COUNSEL & CORP SEC	AAward	+53K sh	—	—	53,000
2026-02-17	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsA Award	GENERAL COUNSEL & CORP SEC	AAward	+35K sh	—	—	35,000
2025-12-08	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,300 sh	$31.60	−$41.1K	14,509
2025-12-08	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−2,678 sh	$32.61	−$87.3K	11,831
2025-12-05	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,004 sh	$31.33	−$31.5K	23,590
2025-12-05	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−5,437 sh	$31.08	−$169K	18,153
2025-12-05	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−2,344 sh	$31.76	−$74.4K	15,809
2025-12-04	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−194 sh	$31.32	−$6,075.382	24,594
2025-12-04	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−824 sh	$30.76	−$25.3K	24,788
2025-12-03	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+6,000 sh	—	—	25,612
2025-12-03	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−898 sh	$30.34	−$27.2K	21,006
2025-12-03	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,394 sh	$30.85	−$43K	19,612
2025-12-03	STOKStoke Therapeutics, Inc. · Performance Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−6,000 sh	—	—	0
2025-12-02	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−868 sh	$30.14	−$26.2K	21,904
2025-12-02	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,416 sh	$29.56	−$41.9K	22,772
2025-12-01	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+12.4K sh	—	—	24,188
2025-12-01	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−12.4K sh	—	—	0
2025-10-03	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+10K sh	$9.15	+$91.5K	21,831
2025-10-03	STOKStoke Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−10K sh	—	—	34,800
2025-10-03	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−10K sh	$25.07	−$251K	11,831
2025-09-03	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−6,345 sh	$20.07	−$127K	11,831
2025-09-02	STOKStoke Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−9,150 sh	—	—	15,801
2025-09-02	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+9,150 sh	$7.07	+$64.7K	33,098
2025-09-02	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−14.9K sh	$20.14	−$300K	18,176
2025-08-29	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−850 sh	$20.00	−$17K	23,948
2025-08-29	STOKStoke Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−850 sh	—	—	24,951
2025-08-29	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+850 sh	$7.07	+$6,009.5	24,798
2025-08-18	STOKStoke Therapeutics, Inc.S Sale	GENERAL COUNSEL & CORP SEC	SSale	−1,683 sh	$18.24	−$30.7K	23,948
2025-08-14	STOKStoke Therapeutics, Inc.M Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	+6,000 sh	—	—	25,631
2025-08-14	STOKStoke Therapeutics, Inc. · Performance Stock UnitsM Exercise/Conversion	GENERAL COUNSEL & CORP SEC	MExercise/Conversion	−6,000 sh	—	—	6,000
2025-08-14	STOKStoke Therapeutics, Inc. · Performance Stock UnitsA Award	GENERAL COUNSEL & CORP SEC	AAward	+12K sh	—	—	12,000

Recent filings

Accepted (ET)
Oct 24
Allan Jonathan0001966716-26-000014
SEC(opens sec.gov)
Aug 184
Allan Jonathan0001966716-26-000012
SEC(opens sec.gov)
Jun 184
Allan Jonathan0001966716-26-000010
SEC(opens sec.gov)
Mar 244
Allan Jonathan0001966716-26-000008
SEC(opens sec.gov)
Mar 194
Allan Jonathan0001966716-26-000006
SEC(opens sec.gov)
Mar 174
Allan Jonathan0001966716-26-000004
SEC(opens sec.gov)
Feb 194
Allan Jonathan0001966716-26-000002
SEC(opens sec.gov)

Companies

Stoke Therapeutics, Inc.GENERAL COUNSEL & CORP SECSTOK

Address

C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE

BEDFORD, MA, 01730